MissionIR News - Seeking Alpha Publishes Article Featuring FluoroPharma Medical

Share Article

Article features FluoroPharma Medical alongside General Electric, Royal Philips Electronics and other industry leaders

The medical imaging industry continues to grow, saving countless lives, as even small providers can now realize a hefty return on their investment in a relatively short time

MissionIR would like to highlight FluoroPharma Medical, Inc. (OTCBB: FPMI). FluoroPharma Medical is a biopharmaceutical company focused on discovering and developing patented Positron Emission Tomography (PET) imaging products to improve patient management by evaluating cardiac disease at the cellular and molecular levels. The company is currently advancing two products in clinical trials to fulfill critical unmet medical needs.

Today, Seeking Alpha published the following article featuring FluoroPharma Medical: http://seekingalpha.com/article/321920

The article titled “Medical Imaging Stocks” reviews the significance of medical imaging, one of the top medical developments of the last millennium, and the principle imaging technologies used today. The medical imaging industry continues to grow, saving countless lives, as even small providers can now realize a hefty return on their investment in a relatively short time.

Unique in its ability to get down to cellular processes, PET, a cutting-edge, rapidly growing branch of nuclear medicine, uses short-lived radioactive chemicals that can, depending upon the chemicals used, provide vital information regarding neurological diseases, heart disease, and cancer. Unlike traditional imaging modalities - MRI, CT, and Ultrasound - that reveal the anatomical abnormalities and cause for disease, PET provides insight into physiology and can detect disease before anatomical manifestation is identified.

FluoroPharma Medical does not focus on PET equipment, but rather the critically important imaging agents, the chemicals that allow PET technology to see the cellular processes associated with heart disease and other major diseases. Clinical trials have already confirmed FluoroPharma's imaging agents are safe and are now establishing their efficacy.

The company's broad technology platform was developed by scientists at the Massachusetts General Hospital and Harvard Medical School. FluoroPharma Medical has four issued U.S. patents, with seven pending applications, together with strong international protection. According to GAI, the market for molecular imaging agents currently exceeds $1.7 billion annually and promises rapid growth for the foreseeable future.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit http://MissionIR.com

To connect with MissionIR via Facebook, please visit http://Facebook.com/MissionIR

To connect with MissionIR via Twitter, please visit http://Twitter.com/MissionIR

Please read FULL disclaimer on the MissionIR website: http://Disclaimer.MissionIR.com

Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

MissionIR Communications
Visit website